STOCK TITAN

[8-K] Emmaus Life Sciences, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Emmaus Life Sciences, Inc. reported that director Jon Kuwahara resigned from its board. The resignation was dated April 13, 2026 and becomes effective April 15, 2026. The company also identified a cover page interactive data file as Exhibit 104 embedded within the inline XBRL document.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Resignation date April 13, 2026 Date Jon Kuwahara submitted resignation as director
Effective resignation date April 15, 2026 Date Jon Kuwahara’s resignation becomes effective
Signature date April 14, 2026 Date the report was signed by Willis Lee
Exhibit number 104 Cover Page Interactive Data File in inline XBRL
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"
inline XBRL technical
"Cover Page Interactive Data File (embedded within the inline XBRL Document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Exhibit 104 regulatory
"Exhibit Number | | Description 104 | | Cover Page Interactive Data File"
false 0000822370 0000822370 2026-04-13 2026-04-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 13, 2026

 

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35527   87-0419387
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

21250 Hawthorne Boulevard, Suite 800, Torrance, CA   90503
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (310) 214-0065

 

 

(Former name or former address, if changed, since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

 

Resignation of Director

 

On April 13, 2026, Jon Kuwahara resigned as a director of Emmaus Life Sciences, Inc., effective April 15, 2026.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number
  Description
104   Cover Page Interactive Data File (embedded within the inline XBRL Document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 14, 2026 EMMAUS LIFE SCIENCES, INC.
     
  By: /s/ WILLIS LEE
  Name:  Willis Lee
  Title: Chairman and Chief Executive Officer

 

2

 

FAQ

What did Emmaus Life Sciences (EMMA) announce in this 8-K filing?

Emmaus Life Sciences announced that director Jon Kuwahara resigned from its board. His resignation was dated April 13, 2026 and is effective April 15, 2026. The filing also lists a cover page interactive data file as Exhibit 104 in the inline XBRL document.

When is Jon Kuwahara’s resignation from Emmaus Life Sciences (EMMA) effective?

Jon Kuwahara’s resignation as a director of Emmaus Life Sciences is effective April 15, 2026. The filing states that he resigned on April 13, 2026, with that effective date, providing a brief transition window between the resignation date and effectiveness.

Which item of the 8-K covers the director resignation at Emmaus Life Sciences (EMMA)?

The director resignation is disclosed under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. This item specifically notes that director Jon Kuwahara resigned effective April 15, 2026.

Who signed the Emmaus Life Sciences (EMMA) 8-K reporting the director resignation?

The 8-K was signed on behalf of Emmaus Life Sciences by Willis Lee. The filing identifies Willis Lee as the company’s Chairman and Chief Executive Officer and shows the signature date as April 14, 2026, following the reported resignation date.

What exhibit was included with Emmaus Life Sciences’ (EMMA) 8-K about the director resignation?

The filing lists Exhibit 104 as a cover page interactive data file. It states that this file is embedded within the inline XBRL document, providing structured data representation of the cover page information associated with the 8-K filing.

Filing Exhibits & Attachments

3 documents